Journal
IMMUNOLOGY AND CELL BIOLOGY
Volume 90, Issue 1, Pages 85-94Publisher
WILEY
DOI: 10.1038/icb.2011.100
Keywords
cancer; HDAC inhibitor; cell death; clinical; biomarker
Categories
Funding
- Cancer Research UK
- Medical Research Council
- Leukaemia and Lymphoma Research
- European Union
- MRC [G1000807] Funding Source: UKRI
- Medical Research Council [G1000807] Funding Source: researchfish
Ask authors/readers for more resources
Reversible acetylation mediated by histone deacetylases (HDACs) influences a broad repertoire of physiological processes, many of which are aberrantly controlled in tumor cells. As HDAC inhibition prompts tumor cells to enter apoptosis, small-molecule HDAC inhibitors have been developed as a new class of mechanism-based anti-cancer agent, many of which have entered clinical trials. Although the clinical picture is evolving and the precise utility of HDAC inhibitors remains to be determined, it is noteworthy that certain tumor types undergo a favorable response, in particular hematological malignancies. Vorinostat and romidepsin have been approved for treating cutaneous T-cell lymphoma in patients with progressive, persistent or recurrent disease. Here, we discuss developments in our understanding of molecular events that underlie the anti-cancer effects of HDAC inhibitors and relate this information to the emerging clinical picture for the application of these inhibitors in the treatment of cancer. Immunology and Cell Biology (2012) 90, 85-94; doi: 10.1038/icb.2011.100; published online 29 November 2011
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available